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Directly observed antiretroviral therapy: a systematic review 
and meta-analysis of randomised clinical trials
Nathan Ford, Jean B Nachega*, Mark E Engel*, Edward J Mills
Summary
Background Directly observed therapy has been recommended to improve adherence for patients with HIV infection 
who are on highly active antiretroviral therapy, but the beneﬁ  t and cost-eﬀ  ectiveness of this approach has not been 
established conclusively. We did a systematic review and meta-analysis of randomised trials of directly observed 
versus self-administered antiretroviral treatment.
Methods We did duplicate searches of databases (from inception to July 27, 2009), searchable websites of major HIV 
conferences (up to July, 2009), and lay publications and websites (March–July, 2009) to identify randomised trials 
assessing directly observed therapy to promote adherence to antiretroviral therapy in adults. Our primary outcome 
was virological suppression at study completion. We calculated relative risks (95% CIs), and pooled estimates using a 
random-eﬀ  ects method. 
Findings 12 studies met our inclusion criteria; four of these were done in groups that were judged to be at high risk of 
poor adherence (drug users and homeless people). Ten studies reported on the primary outcome (n=1862 participants); 
we calculated a pooled relative risk of 1·04 (95% CI 0·91–1·20, p=0·55), and noted moderate heterogeneity between 
the studies (I²= 53·8%, 95% CI 0–75·7, p=0·0247) for directly observed versus self-administered treatment.
Interpretation Directly observed antiretroviral therapy seems to oﬀ  er no beneﬁ  t over self-administered treatment, 
which calls into question the use of such an approach to support adherence in the general patient population.
Funding None.
Introduction
Highly active antiretroviral therapy (HAART) has greatly 
aﬀ  ected the course of disease for patients with HIV 
infection, resulting in an important reduction in AIDS-
related morbidity and mortality in both developed and 
developing countries.
1 Strategies to improve adherence 
remain crucial for successful outcomes on any HAART 
regimen. HAART requires lifelong and high ad  herence 
to ensure maximum virological outcomes,
2 prevent 
antiretroviral drug resistance,
3 prevent disease 
progression, and improve survival.
4 Many behavioural 
interventions have been developed to support ad  herence 
such as adherence case management, counselling, 
pharmacist-based education, telephone support, 
reminder devices, home visits by nurses, and directly 
observed therapy.
5 Of these interventions, directly 
observed therapy is perhaps the most contentious.
6,7 
In directly observed therapy, a health-care worker or 
other designated individual witnesses the patient 
swallowing their drugs. The intervention was developed 
to support adherence to tuberculosis programmes in the 
1960s,
8 and has been promoted by WHO since 1994 as 
part of its global tuberculosis control strategy. However, 
concerns have been raised with respect to the poor 
evidence of eﬀ   ectiveness and the high cost of this 
approach. Results of a systematic review of randomised 
trials on treatment for tuberculosis showed no beneﬁ  t to 
cure or completion of treatment  of directly observed 
versus self-administered treatment,
9 and critics have 
raised concerns that the intervention is coercive to 
patient autonomy.
10
Tuberculosis and HIV treatment diﬀ  er in several ways. 
The most important diﬀ   erence for patients is that 
tuberculosis treatment (directly observed therapy short-
course [DOTS]) is of a ﬁ  nite duration (6–8 months for 
non-resistant strains) whereas HAART is a lifelong 
treatment. Therefore, concerns about the feasibility and 
cost-eﬀ   ectiveness of directly observed therapy for 
tuberculosis are even more relevant for HAART.
 
Nevertheless, the intervention has been promoted as a 
potential adherence support strategy for HAART, largely 
on the basis of small observational studies.
11
Adherence support is an essential component of 
HAART. Direct observation has been proposed as a 
strategy to promote adherence and avoid drug resistance. 
However, patients and health services could both be 
aﬀ  ected by the potential burden of implementation of 
such a strategy. Therefore, clear evidence of beneﬁ  t is 
needed. We did a systematic review and meta-analysis of 
randomised trials of directly observed versus self-
administered antiretroviral treatment.
Methods
Inclusion criteria
We included all randomised trials assessing directly 
observed therapy as an intervention to promote adherence 
to antiretroviral therapy as a primary or secondary 
outcome within any population in any setting. We 
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regarded the supervised swallowing of HAART pills as 
direct observation; this strategy contrasts with the DOTS 
framework for tuberculosis, which provides a range of 
approaches to patient support in addition to observation.
12 
We included trials of any duration or exposure to directly 
observed therapy, irrespective of regularity, and examined 
diﬀ  erences in a sensitivity analysis. We included studies 
of adults receiving any HAART combination in any 
dosing format. Non-randomised studies were excluded.
Search strategy
We searched Medline via PubMed, EmBase, Cochrane 
Central Register of Controlled Trials, CINAHL, PsycInfo, 
LILACS, Current Controlled Trials, and ClinicalTrials.gov 
for articles and reviews (from inception of every database 
to July 27, 2009) using a highly sensitive search strategy 
that combined key terms associated with adherence (eg, 
“adherence”, “compliance”, “directly observed”, “DOT”), 
medical subject headings  (“HIV” or “acquired immuno-
deﬁ  ciency syndrome”), and search terms for randomised 
trials. A full list of search terms is given in the study 
protocol. We used the same strategy on the searchable 
websites of all conferences of the International AIDS 
Society (April, 1985–July, 2009), and every Conference on 
Retroviruses and Opportunitistic Infections (January, 
1997–February, 2009). NF and EJM searched 
independently, in duplicate, the full list of databases 
between March and July, 2009.
We hand searched abstracts of the International 
Conference on HIV Treatment Adherence (International 
Association of Physicians in AIDS Care; March, 2006–
April, 2009). We also searched several lay publications 
and websites between March and July, 2009: The Body, 
the Canadian AIDS Treatment Information Exchange 
publications, AIDS Treatment News, Google Scholar, and 
the Networked Digital Library of Theses and Disserta-
tions. Last, we complemented the search by reviewing 
bibliographies of relevant papers and contacting 
individual clinical researchers and AIDS trials groups by 
email and phone (National Institute of Mental Health, 
International AIDS Society, and International Association 
of Physicians in AIDS Care). No language or date 
restrictions were placed on searches. Our search 
identiﬁ  ed all studies matching our inclusion criteria that 
were suggested by these groups. We contacted all 
potentially relevant study authors by email and telephone 
for details on their trials. JBN was primary investigator 
on a trial in South Africa.
13
Study selection
NF and EJM used a predeﬁ  ned protocol to independently, 
in duplicate, scan all abstracts for the suggestion that 
directly observed therapy was used, and obtain the full 
text of relevant articles. From the full text of candidate 
studies (either in full peer-reviewed publications, as 
conference abstracts, or as articles that had not been 
peer-reviewed), NF and EJM independently assessed 
eligibility. Reviewers were not masked to study authors, 
conclusions, and outcomes because masking has been 
shown to have little eﬀ  ect on systematic reviews.
14 To 
obtain full information for conference abstracts and 
registered trials, we attempted contact with all study 
authors for full information by email and telephone 
communication. Once all potentially relevant full-text 
articles and abstracts were identiﬁ  ed, we consulted as a 
team (NF, JBN, EJM) to achieve consensus regarding 
eligibility, and consulted an arbitrator (MEE) for 
adjudication.
Data extraction
Data extraction was done independently and in duplicate 
with a standardised, previously tested form. NF and EJM 
gathered information about the study setting, study 
populations, sample size, and methods of adherence 
measurement. Since there is no gold standard for 
assessment of adherence to medication,
15 we included 
diﬀ   erent measures of adherence, as reported in the 
studies. Our primary endpoint was viral suppression at 
study endpoint. Secondary outcomes were self-reported 
adherence, immunological progression (as measured by 
CD4 T cells per mm³), loss to follow-up, all-cause mortality, 
development of resistance mutations, and new or 
recurrent AIDS-deﬁ  ning illnesses. We entered the data 
into an electronic database (MS Access) such that duplicate 
entries existed for each study and when the two entries 
did not match we reached consensus through discussion. 
We judged study quality according to a predeﬁ  ned 
assessment instrument that assessed randomisation 
method, adjustment of experimental confounders, 
allocation concealment, masking of analysts, objectivity of 
outcome measures, use of intention-to-treat analysis, and 
less than 20% of participants lost to follow-up.
Statistical analysis
To assess inter-rater reliability on inclusion of articles, we 
calculated the   statistic, which provides a measure of 
inter-observer agreement
 independent of chance.
16 NF 
and EJM did all statistical analyses. We calculated the 
relative risk (RR, 95% CI) of the primary and secondary 
outcomes according to the number of events reported in 
the original studies or sub-studies as intention-to-treat 
analyses. If studies did not report intention to treat, we 
analysed outcomes as all-patients randomised.
17 In the 
unlikely event of zero outcome events in one group in a 
trial, we prepared to apply the Haldane method and add 
0·5 to each group.
18
Study outcomes were pooled with the DerSimonian-
Laird random-eﬀ  ects  method,
18  which recognises and 
anchors studies as a sample of all potential studies, and 
incorporates an additional between-study component to 
the estimate of variability.
18 We calculated the I² statistic 
(95% CI) for each analysis as a measure of the proportion 
of the overall variation that is attributable to between-
study heterogeneity.
18 We ran a sensitivity analysis on our 
For more on medical subject 
headings see http://www.nlm.
nih.gov/mesh
For the study protocol see 
http://tinyurl.com/ylyb6zu
For the Networked Digital 
Library of Theses and 
Dissertations see 
http://www.ndltd.org
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primary outcome using a Bayesian random-eﬀ  ects model 
with Monte Carlo Markov chain simulations of 
variability.
19  In view of the expected small number of 
included trials we did univariate sensitivity analysis with 
the χ² test to assess the eﬀ  ect of methodological variables 
on outcome: groups at high risk of non-adherence versus 
the general population, intervention type (full vs partial 
directly observed therapy), allocation concealment, 
location of study, previous treatment experience, and the 
eﬀ   ect of short-term (≤6 months) versus long-term 
(>6 months) study duration. We assessed change in CD4 
T-cell count by applying a weighted mean diﬀ  erence 
meta-analysis and transformed data to mean (SD) when 
reported as median (range).
20 A forest plot is shown for 
the analysis of directly observed versus self-administered 
treatment for every study reporting the primary outcome, 
with individual study proportions (95% CIs), and the 
overall DerSimonian-Laird pooled estimate.
All p values are two-sided; we judged the threshold of 
signiﬁ   cance to be α=0·05. Analyses were done with 
StatsDirect (version 2.5.2), Stata (version 11.0), and 
OpenBUGS (version 2.1).
Role of the funding source
There was no funding source for this study. NF and EJM 
had full access to the data and take responsibility for 
submission for publication.
Results
Figure 1 shows the ﬂ  ow diagram of study selection for the 
analysis. 83 studies passed the ﬁ  rst screening of articles 
from titles and abstracts; there was near perfect agreement 
between reviewers on inclusion of abstracts for further 
analysis ( =0·91). A further seven studies were included 
from article bibliographies and conference abstracts, and 
78 were excluded because they did not meet our inclusion 
criteria (one because the author did not respond so we 
failed to secure suﬃ   cient data
21). Overall, 12 studies were 
included for analysis (table 1): six from the USA,
22,23,27,30–32 
ﬁ  ve from Africa (Mozambique,
24 Kenya,
25 Nigeria,
26 and 
South Africa
13,29), and one multicentre study from the USA 
and South Africa.
28 All full-text papers and abstracts were 
published in English. Authors provided additional data 
for six abstracts.
13,26,29–32
When we examined study reporting of methodological 
features in full-text studies and where authors provided 
information (n=7), we found moderate reporting of 
important methodological issues. Six studies reported 
sequence generation,
13,22–25,28 three reported allocation 
concealment,
13,24,25 none reported masking of study 
analysts, and four reported results as a full intention-to-
treat analysis.
 13,22,27,28 Five studies reported less than 20% 
of participants lost to follow-up.
13,23,24,27,28 The method of 
implementation of directly observed therapy varied 
across studies. Two studies used full directly observed 
therapy (observation of every single dose),
23,31 and the 
remainder had a partial regimen whereby only a 
proportion of doses was observed. Six studies
25,28–32 used 
health workers as observers, and all others used 
community or peer supporters. All studies used self-
administered treatment as the control intervention.
We pooled all studies that reported our primary 
outcome of viral suppression at study completion 
(n=1862 participants) to assess the eﬀ  ectiveness  of 
directly observed versus self-administered treatment. 
The combined relative risk from these studies indicated 
that the diﬀ  erence was not signiﬁ  cant (p=0·55; ﬁ  gure 2). 
The Bayesian sensitivity analysis reinforced this ﬁ  nding: 
RR 1·05, 95% credible interval 0·96–1·14. Moderate 
heterogeneity was recorded for the studies included in 
the meta-analyses (I²= 53·8%, 95% CI 0–75·7, p=0·0247). 
We recorded similar mean event rates for virological 
suppression across the pooled trials: 0·53 (95% CI 
0·46–0·61) for directly observed therapy versus 0·50 
(0·39–0·59) for self-administered treatment.
We further analysed these data to look at the diﬀ  erence 
between directly observed and self-administered 
treatment in several subgroups for studies reporting the 
primary outcome of viral suppression  (webappendix). 
From the four studies that enrolled populations at high 
risk of non-adherence (drug users
23,27,32 and homeless
30), 
we calculated a RR of 1·31 (95% CI 1·00–1·71, p=0·0464; 
I²=27·6%, 95% CI 0–75·9, p=0·24). For general 
populations in the remaining six studies,
13,22,25,26,28,29 the RR 
was 0·96 (0·82–1·13, p=0·63; I²=58·3%, 0–81·1, 
p=0·0348). No signiﬁ  cant diﬀ  erences in outcome were 
recorded for: studies using full
23 versus partial directly 
observed therapy
13,22,25–30,32   (p=0·40); studies reporting 
allocation concealment
13,25 versus those that did not report 
942 articles screened by 
title and abstract
26 eligible for inclusion
859 excluded
 382  duplicates
  477 not relevant
62 excluded
  23 not randomised
 18  reviews  or  commentaries
 21  duplicates
16 excluded
1 ongoing
1 did not use 
   directly observed therapy
1 no data provided
10 supplementary reports 
      to counted studies
3 not randomised
12 included in analysis
83 full-text articles 
reviewed
5 articles identiﬁed from 
bibliographies
2 articles identiﬁed from 
conference abstracts
Figure 1: Flow diagram for selection of studies
See Online for webappendix
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allocation concealment
22,23,26–30,32 (p=0·27); or studies done 
in Africa
13,25,26,29  versus those done in the USA
22,23,27,30,32 
(p=0·60). Three studies reported on previous treatment 
experience,
22,27,33 but information was insuﬃ   cient  to 
undertake a sensitivity analysis. Diﬀ  erence in duration of 
study (≤6 months
22,23,26,32  vs >6 months
13,25,27,28,30) did not 
signiﬁ  cantly  aﬀ   ect outcome (p=0·82), but  trials of 
6 months’ duration or less seemed to be associated with 
improved outcome under directly observed therapy (RR 
1·24, 95% CI 1·03–1·50, p=0·212; I²=32·5%, 95% CI 
0–77·2, p=0·21). In a post-hoc analysis, we compared 
studies published in peer review journals with conference 
abstracts and recorded no signiﬁ  cant  diﬀ  erences  in 
outcomes (p=0·56).
Table 2 shows data for the main secondary outcomes, 
and we were also able to extract data for resistance 
mutations, and new or recurrent AIDS-deﬁ  ning 
illnesses. Self-reported adherence—deﬁ  ned as any pills 
missed during a limited (<1 week) recall period—was 
available for six studies (n=1308; table 2). For directly 
observed versus self-administered treatment, RR was 
1·02 (95% CI 0·98–1·06, p=0·29). Two of the trials 
reported adherence data on only a subset of patients.
22,25 
Adherence  in both groups was high: the overall mean 
adherence at study completion was 89% (SD 12·7) for 
directly observed and 88% (11·6) for self-administered 
treatment.
Eight studies were included in our assessment of 
immunological changes between groups at study 
conclusion (n=1577; table 2). We were unable to show a 
signiﬁ   cant weighted mean diﬀ   erence for CD4 T-cell 
count between the treatment groups (0·35, 95% CI –2·49 
to 3·20, p=0·80); data were weighted by the inverse 
variance method.
34 For assessment of loss to follow-up, 
pooled data from nine trials (n=1635) gave an RR of 1·00 
(0·75 to 1·32, p=0·97). One study reported a high number 
of refusals to participate in the intervention group after 
randomisation,
27 but this did not contribute to identiﬁ  able 
heterogeneity between studies (I²=0%, 95% CI 0–54·4, 
p=0·45). From data on all-cause mortality from seven 
trials (n=1490), we recorded a pooled RR of 0·67 (95% CI 
0·41 to 1·07, p=0·09), indicating that method of therapy 
did not aﬀ  ect all-cause mortality (table 2).
The development of resistance mutations was only 
reported for two trials,
28,35 with no diﬀ  erence between 
directly observed and self-administered treatment (RR 
1·66, 95% CI 0·47–5·90, p=0·42). Three trials reported 
on AIDS-deﬁ  ning events,
13,22,28 and the diﬀ  erence between 
the treatment groups was not signiﬁ  cant  (0·92, 
0·44–1·95, p=0·83).
Discussion
Our study shows no beneﬁ  t to virological suppression of 
directly observed versus self-administered antiretroviral 
Location of study 
population
Mean age 
(years)
Number of 
patients
Men Intervention Duration of 
follow-up
Primary outcome
Type Observer and location Duration
Wohl et al (2006)
22 Clinic, USA 82% more 
than 30 years
166 125 (75%) Partial DOT 
(once daily)
Community worker, 
clinic
6 months 6 months Viral load <400 copies per mL
Macalino et al (2007)
23 Drug users, USA 42 87 61 (70%) Full DOT 
(once daily)
Outreach worker, 
community
3 months 3 months Viral load <50 copies per mL
Pearson et al (2007)
24 Clinic,
Mozambique
36 350 162 (46%) Partial DOT 
(once daily)
Peer supporters, clinic 6 weeks 12 months Adherence (30-day recall)
Sarna et al (2008)
25 Clinic, Kenya 37 234 85 (36%) Partial DOT (once 
daily, twice weekly)
Nurse, clinic 6 months 18 months Viral load <400 copies per mL
Taiwo et al (2008)
26 Clinic, Nigeria 33 500 220 (44%) Partial DOT 
(once daily)
Peer supporters, 
community
6 months 6 months Viral load <200 copies per mL
Maru et al (2009)
27* Drug users, USA 44 141 97 (69%) Partial DOT 
(once daily)
Outreach worker, 
mobile clinic
6 months 12 months Viral load <400 copies per mL
Nachega et al (2009)
13 Clinic, South 
Africa
36 274 116 (43%) Partial DOT 
(once daily)
Peer supporter, 
community
24 months 24 months Viral load <50 copies per mL
Gross et al (2009)
28 Clinics, USA and 
South Africa
39 243 192 (79%) Partial DOT 
(weekdays only)
Medical practitioner, 
clinic and community
6 months 12 months Viral load <200 copies per mL
Naidoo et al (2009)
29 Clinic, South 
Africa
·· 58 ·· Partial DOT 
(weekdays only)
Nurse, clinic 10 months ·· Viral load <200 copies per mL
Bangsberg et al (2009)
30 Homeless, USA 42 82 65 (79%) Partial DOT 
(weekdays only)
Health worker, 
community
3 months 12 months Viral load <400 copies per mL
Grodensky et al (2009)
31 Prisoners, USA 38 43 34 (79%) Full DOT 
(twice daily)
Health worker, prison 12 months 12 months Adherence (% of doses taken)
Arnsten et al (2009)
32 Drug users, USA 47 77 41 (53%) Partial DOT 
(weekdays only)
Clinic staﬀ  , clinics 6 months 6 months Viral load <400 copies per mL
Data are number (%) unless otherwise indicated. Control group was self-administered treatment for all studies. DOT=directly observed therapy. ··=data unavailable. *Implementation of this trial was reported in 
an earlier paper.
33
Table 1: Baseline characteristics of participants and study design of clinical trialsArticles
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treatment in people with HIV infection. Despite 
expectations that directly observed therapy could be an 
eﬀ  ective intervention to promote adherence both for the 
general population
11 and for groups at high risk of poor 
adherence,
36 we did not ﬁ  nd any evidence to support 
such use.
Our study is not the ﬁ  rst to question the eﬀ  ectiveness of 
directly observed therapy for chronic disease care: a 
similar absence of eﬀ  ect was reported for tuberculosis 
treatment by Volmink and Garner’s
9 meta-analysis (RR 
1·02, 95% CI 0·86–1·21). Such lack of success in both 
meta-analyses could be caused by attrition due to intensive 
clinic visitation requirements for daily observation that 
not all patients can meet,
37 resistance by patients to losing 
their autonomy
38 and a desire to take responsibility for 
their own treatment,
39 absence of actual delivery of the 
intervention, or patients maintaining excellent adherence 
irrespective of the intervention, indicating that self-
administered treatment is successful for long-term care.
6 
Additionally, treatment eﬀ  ects were small across all trials, 
such that a much larger sample size would be needed to 
measure an eﬀ  ect; small trials in general populations are 
underpowered to show important eﬀ  ects.
In our sensitivity analyses, we recorded marginal 
beneﬁ  t of directly observed therapy in groups that were 
judged to be at high risk of non-adherence and in trials of 
short duration (<6 months). Although not deﬁ  nitive, 
these ﬁ  ndings provide direction for future research with 
directly observed therapy to investigate the potential for 
targeted interventions of ﬁ  nite duration and for speciﬁ  c 
groups. Some researchers have suggested that directly 
observed therapy might oﬀ  er beneﬁ  t during the period of 
intervention, but that this beneﬁ  t could wane afterwards.
7 
We did not consider this possibility in our a priori 
sensitivity analysis, but note that of the trials that included 
a follow-up period after the study period, none of their 
ﬁ  ndings indicated any beneﬁ  t.
25,27,28,30 Therefore, although 
directly observed therapy has been promoted to reinforce 
adherence, any beneﬁ  t will probably wane after the study 
period for the intervention, as has been reported for other 
punctual adherence interventions.
40
Strengths of this systematic review are explicit eligibility 
criteria, and the comprehensive search that identiﬁ  ed 
several eligible articles that were not published or 
available via electronic databases. We contacted all 
authors to complete missing information, and in most 
cases this was provided. Independent reviewers assessed 
eligibility and agreement was high.
Although our a priori analysis of heterogeneity did not 
ﬁ  nd diﬀ  ering eﬀ  ects across study populations, duration, 
or quality, the diﬀ   erence in population groups and 
intervention used (full or partial directly observed 
therapy) warrants attention to possibly diﬀ  ering eﬀ  ects 
across speciﬁ  c populations or delivery of the intervention. 
We used a random-eﬀ  ects model to pool results since 
the model assumes that individual studies have 
estimated diﬀ   erent treatment eﬀ   ects, but we cannot 
discount some degree of heterogeneity. We also 
undertook sensitivity analyses to assess diﬀ  erences in 
trial location, study duration, diﬀ  erent populations, and 
type of intervention (full or partial directly observed 
therapy) and these were consistent with the overall 
pooled estimate of eﬀ   ect. Nevertheless, important 
diﬀ   erences in population groups could still lead to 
substantial diﬀ   erences in outcomes; the fact that 
individual trials found opposing results with respect to 
beneﬁ   t of directly observed therapy underscores the 
importance of considering contextual factors in 
assessment of adherence interventions.
Any assessment of adherence is limited by the absence 
of a gold standard for such assessment.
15 We used a 
pharmacodynamic outcome (viral load) as our major 
outcome because we did not expect pharmacodynamics 
to be aﬀ  ected by a placebo eﬀ  ect. We note that viraemia 
can be aﬀ  ected by both adherence and drug resistance; 
drug resistance was not consistently assessed across 
studies, but no diﬀ  erence was recorded for studies in 
which data were available. We included studies that used 
both full and partial directly observed therapy for a range 
of study periods. Our sensitivity analysis did not ﬁ  nd 
evidence that either type or duration of intervention 
aﬀ   ected study outcomes, although we recognise that 
short interventions might have residual eﬀ  ects through 
education of patients experiencing problems with 
adherence. The fact that all secondary outcomes (self-
reported adherence, immunological change, loss to 
follow-up, all-cause mortality, resistance mutations, and 
AIDS-deﬁ  ning events) were not signiﬁ  cant supports the 
inference that the intervention had no major eﬀ  ects on 
virological suppression.
Another limitation, general to any systematic review, is 
the possibility that we did not capture all trial data. We 
Figure 2: Relative risk for viral suppression at study completion with directly observed versus self-administered 
antiretroviral treatment
Data for viral suppression were not reported in two studies.
24,31 Weights were calculated from random-eﬀ  ects 
analysis. DOT=directly observed therapy.
Relative risk (95% CI) Relative risk (95% CI) Weight (%)
Wohl et al (2006)22
Macalino et al (2007)23
Sarna et al (2008)25
Taiwo et al (2008)26
Maru et al (2009)27
Nachega et al (2009)13
Gross et al (2009)28
Naidoo et al (2009)29
Bangsberg et al (2009)30
Arnsten et al (2009)32
Overall
1·00 (0·75–1·33)
1·63 (1·01–2·64)
0·90 (0·73–1·12)
1·23 (1·05–1·44)
1·02 (0·76–1·38)
0·89 (0·71–1·12)
0·72 (0·51–1·02)
0·95 (0·68–1·33)
1·44 (0·72–2·89)
1·60 (0·98–2·62)
1·04 (0·91–1·20)
11·27%
6·01%
13·83%
16·46%
10·83%
13·38%
9·31%
9·62%
3·41%
5·86%
100·00%
Self-administered
treatment better
DOT better
0·5 1·0 2·0 3·0Articles
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failed to gain suﬃ   cient information for one completed 
trial.
21 However, the results of this trial have been reported 
in a conference abstract that concluded that there was no 
diﬀ   erence between directly observed and self-
administered treatment.
41 Data from six studies included 
in the meta-analysis were derived from abstracts that 
have yet to be published as full studies. Although 
inclusion of these abstracts provides reassurance that all 
available data were captured, it could result in publication 
bias; however, results from our sensitivity analysis 
indicate no signiﬁ  cant diﬀ  erence between abstracts and 
studies published in journals (webappendix).
Randomised trials to assess the beneﬁ   t of directly 
observed therapy are challenging because part of the 
inclusion criteria needs to be that patients are poorly 
adherent to potentially measure an eﬀ  ect. Since patients 
on HAART are generally adequately adherent
42 and the 
degree of adherence can vary while still suppressing 
viraemia,
43 researchers face a major challenge to enrol a 
large enough population size to detect a diﬀ  erence, as 
indicated by the similar event rates of virological 
suppression across the pooled trials.
44,45 Possible 
explanations for viraemia beyond adherence include 
polypharmacy, drug resistance, treatment failure, and 
unknown eﬀ  ects of the disease or drugs.
46,47 Thus use of 
viral suppression as a primary outcome is important 
from a clinical perspective, but challenging from a 
methodological perspective. Additionally, although not 
signiﬁ   cant, we recorded decreased mortality in the 
intervention group, suggesting that mortality should be 
routinely reported as an outcome in future trials.
Our analysis should be interpreted according to the 
size of treatment eﬀ   ects reported, and not only the 
statistical signiﬁ  cance of these eﬀ  ects. The conﬁ  dence 
intervals around our primary outcome show that even if 
the treatment eﬀ   ect were at the upper interval of 
eﬀ  ectiveness, widespread use of directly observed therapy 
would not be justiﬁ  ed. Supporters of directly observed 
therapy have argued that the eﬀ  ect of such an intervention 
goes beyond observation of drug doses for tuberculosis
48 
and HIV,
49 by promoting patient education and interaction 
with health systems and peer supporters. However, the 
absence of a measurable beneﬁ  t together with the burden 
of directly observed therapy on patients and health 
services calls into question the eﬀ   ectiveness of this 
intervention (as distinct from auxiliary forms of support) 
for promotion of adherence for the general patient 
population. The feasibility and cost of daily observation 
of lifelong treatment should also be taken into account, 
especially in resource-limited settings where patients 
might have to travel long distances to access under-
resourced health services. Moreover, concerns about the 
intervention being a violation of patient autonomy and 
human rights give further cause for caution in use of this 
approach in the absence of clear beneﬁ  t.
Eﬀ   orts to sustain adherence remain important to 
achieve optimum outcomes with HIV treatment for the 
individual and globally. Continuing eﬀ  orts are needed to 
assess interventions to support adherence, especially for 
groups at high risk of poor adherence. Considerations of 
cost and feasibility of interventions, together with 
acceptability for patients, should be a central part of this 
future research agenda.
Contributors
NF coordinated the study. NF wrote the protocol and MEE supervised the 
protocol design. NF and EJM ran all searches and selected studies, and NF, 
EJM, and JBN consulted as a team to select eligible studies; MEE arbitrated 
the study inclusion. NF did the data extraction, NF and MEE assessed the 
methodological quality, and MEE clariﬁ  ed ambiguities in the data 
extraction. JBN provided guidance on study design and technical issues of 
adherence measurement. EJM provided technical guidance on 
methodological support and adherence measurement issues, and acted as a 
duplicate for study selection, data extraction, and assessment of 
methodological quality. NF undertook all communications with 
investigators of published and unpublished studies. NF and EJM did all 
statistical analyses. JBN undertook additional searches, provided 
unpublished data for one of the included studies, and contributed to data 
interpretation. NF wrote the ﬁ  rst draft of the paper, with participation from 
JBN, MEE, and EJM.
Self-reported adherence CD4 T-cell count (mean 
difference, 95% CI)
Loss to follow-up* All-cause mortality
Wohl et al (2006)
22 1·03 (0·91 to 1·21)† 7 (–51·12 to 65·12) 0·82 (0·46 to 1·45) 0·51 (0·07 to 3·84)
Macalino et al (2007)
23 ·· 44 (–36·28 to 124·28) 0·81 (0·28 to 2·35) ··
Pearson et al (2007)
24 1·06 (0·96 to 1·16) 0·4 (–2·47 to 3·28) 1·00 (0·18 to 5·62) 0·50 (0·16 to 1·53)
Sarna et al (2008)
25 1·02 (0·95 to 1·10)† –14 (–62·95 to 34·95) 1·14 (0·63 to 2·06) 1·40 (0·60 to 3·27)
Taiwo et al (2008)
26 ·· ·· ·· ··
Maru et al (2009)
27 ·· –48·3 (–113·38 to 16·79) 11·44 (2·08 to 66·53) 1·20 (0·16 to 9·10)
Nachega et al (2009)
13 0·97 (0·81 to 1·15) 18 (–26·5 to 62·5) 1·00 (0·42 to 2·38) 0·45 (0·22 to 0·93)
Gross et al (2009)
28 1·01 (0·91 to 1·09) 4 (–5·3 to 13·3) 0·88 (0·48 to 1·57) 0·49 (0·07 to 3·19)
Naidoo et al (2009)
29 ·· ·· 1·13 (0·51 to 2·49) ··
Bangsberg et al (2009)
30 ·· –9 (–96 to 78) 0·30 (0·02 to 4·02) 0·30 (0·02 to 4·02)
Grodensky et al (2009)
31 0·99 (0·79 to 1·21) ·· ·· ··
Arnsten et al (2009)
32 ·· ·· ·· ··
Data are relative risk (95% CI) unless otherwise indicated. ··=data unavailable. *Includes refusals. †Only a subset of patients were followed up for self-reported adherence.
Table 2: Main secondary outcomesArticles
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